Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity

Leukemia. 2006 May;20(5):881-3. doi: 10.1038/sj.leu.2404165.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Adult
  • Arsenic Trioxide
  • Arsenicals / administration & dosage
  • Arsenicals / adverse effects*
  • Arsenicals / therapeutic use
  • Chemical and Drug Induced Liver Injury / complications
  • Chemical and Drug Induced Liver Injury / drug therapy
  • Chemical and Drug Induced Liver Injury / etiology*
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Genetic Predisposition to Disease
  • Humans
  • Incidence
  • Leukemia, Promyelocytic, Acute / diagnosis
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Leukemia, Promyelocytic, Acute / genetics*
  • Liver / drug effects*
  • Liver / enzymology
  • Liver / pathology
  • Liver Function Tests
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics
  • Oxides / administration & dosage
  • Oxides / adverse effects*
  • Oxides / therapeutic use
  • Polymorphism, Genetic*
  • Remission Induction
  • Risk Factors
  • Survival Rate
  • Treatment Outcome

Substances

  • Arsenicals
  • Oxides
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Arsenic Trioxide